NovaBridge Biosciences (FRA:0VY) EBITDA Margin %: 0.00% (As of Dec. 2025)


FRA:0VY NovaBridge Biosciences FRA:0VY
30 GF Score
Price €1.38
! 2 Warning Signs
View Full Analysis

What is NovaBridge Biosciences EBITDA Margin %?

NovaBridge Biosciences FRA:0VY -1.43% 30 EBITDA Margin % is 0.00% as of Dec. 2025. GuruFocus rates FRA:0VY with a GF Score™ of 30/100. The stock has 2 warning signs investors should review. Among 943 Biotechnology companies, NovaBridge Biosciences ranks worse than 106044.43% on this metric.

EBITDA Margin % is calculated as EBITDA divided by its Revenue. NovaBridge Biosciences's EBITDA for the three months ended in Dec. 2025 was €-62.07 Mil. NovaBridge Biosciences's Revenue for the three months ended in Dec. 2025 was €0.00 Mil. Therefore, NovaBridge Biosciences's EBITDA margin for the quarter that ended in Dec. 2025 was 0.00%.

NovaBridge Biosciences  (FRA:0VY) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

NovaBridge Biosciences EBITDA Margin % Related Terms

NovaBridge Biosciences EBITDA Margin % Historical Data

* Premium members only.

The historical data trend for NovaBridge Biosciences's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

NovaBridge Biosciences EBITDA Margin % Chart

NovaBridge Biosciences Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBITDA Margin %
Get a 7-Day Free Trial Premium Member Only -2,613.46 3,331.28 -7,575.52 0.00 0.00

NovaBridge Biosciences Quarterly Data
Sep19 Dec19 Jun20 Sep20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

FRA:0VY vs ELTX, CNTN, INDP: EBITDA Margin % Comparison

For the Biotechnology subindustry, NovaBridge Biosciences's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

NovaBridge Biosciences EBITDA Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, NovaBridge Biosciences's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where NovaBridge Biosciences's EBITDA Margin % falls into.


FRA:0VY
30GF Score
NovaBridge Biosciences FRA:0VY
EBITDA Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

NovaBridge Biosciences EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

NovaBridge Biosciences's EBITDA Margin % for the fiscal year that ended in Dec. 2025 is calculated as

EBITDA Margin %=EBITDA (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-79.775/0
= %

NovaBridge Biosciences's EBITDA Margin % for the quarter that ended in Dec. 2025 is calculated as

EBITDA Margin %=EBITDA (Q: Dec. 2025 )/Revenue (Q: Dec. 2025 )
=-62.072/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBITDA Margin % →
What does a EBITDA Margin % of 0.00% mean?
NovaBridge Biosciences (FRA:0VY) has a EBITDA Margin % of 0.00% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on NovaBridge Biosciences and its competitors. According to the industry distribution chart, NovaBridge Biosciences ranks #999999 out of 943 companies in the Biotechnology industry.
Is NovaBridge Biosciences' EBITDA Margin % too high?
NovaBridge Biosciences' current EBITDA Margin % is 0.00%. Based on the distribution chart, NovaBridge Biosciences ranks #999999 out of 943 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, NovaBridge Biosciences has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does NovaBridge Biosciences' EBITDA Margin % compare to ELTX and CNTN?
According to the Biotechnology industry distribution chart, NovaBridge Biosciences ranks #999999 out of 943 companies for EBITDA Margin %. This places NovaBridge Biosciences in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on NovaBridge Biosciences and its competitors. NovaBridge Biosciences's current EBITDA Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NovaBridge Biosciences stock overvalued right now?
NovaBridge Biosciences (FRA:0VY) has a current EBITDA Margin % of 0.00%. The current EBITDA Margin % is 0.00%. NovaBridge Biosciences' overall GF Score™ is 30/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For NovaBridge Biosciences (FRA:0VY), the current EBITDA Margin % is 0.00% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

NovaBridge Biosciences Business Description

Other Exchanges NBP:USA
Address 2440 Research Boulevard, Suite 400, Rockville, MD, USA, 20850
NovaBridge Biosciences operates as a biotechnology platform, combining business development and clinical research to identify and advance pharmaceutical assets. Its inventive immuno-oncology pipeline consists of three clinical stage programs, givastomig; uliledlimab; and ragistomig. Its core product, givastomig, is a potential in-class CLDN18.2 bispecific antibody for the treatment of gastric cancer and other CLDN18.2-positive gastrointestinal malignancies.
30GF Score

Get the complete analysis for FRA:0VY

EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.38
Price